Market Overview:
The global brigatinib tablet market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel therapies, and growing focus on personalized medicine. Brigatinib is a novel targeted therapy that was approved by the US FDA in 2017 for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. It is available as 30mg, 50mg, and 180mg tablets. The hospital segment accounted for the majority share of the global brigatinib tablet market in 2017 and is expected to continue its dominance during the forecast period. This can be attributed to increasing preference for targeted therapies over traditional chemotherapy regimens among healthcare professionals across regions.
Product Definition:
Brigatinib Tablet is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that has progressed after crizotinib therapy. Brigatinib Tablet is a tyrosine kinase inhibitor.
30mg:
30mg is a high dose, it's used for advanced cancer patients who cannot take chemotherapies or biotherapies. It's an oral drug that belongs to the family of drugs called as SGL-3 type. 30 mg/ml solution is given to the patient and it gets absorbed into the blood cells within 15 minutes and starts working on them.
50mg:
Brigatinib (50mg) is used for the treatment of chronic myeloid leukemia. Chronic myeloid leukemia or CML is a type of cancer that occurs in the blood and bone marrow. It is also known as white blood cell cancer, because it mostly affects leukocytes (white blood cells), including B-lymphocytes, WBCs, platelets and granulocyte counts.
Application Insights:
The hospital application segment led the global brigatinib tablet market in 2017. The segment is expected to witness growth due to rising number of cancer patients seeking treatment in hospitals. Furthermore, increasing government funding for oncology research and development is likely to support the growth of this segment over the forecast period.
Pharmacy was the second largest application of brigatinib tablets, accounting for 29% share of total revenue in 2017 owing to high adoption by oncology physicians as a first line therapy option for patients with advanced solid tumors after other lines of chemotherapy have failed or are not applicable due as they being chemo-resistant or sensitive cancers.
Regional Analysis:
North America dominated the global brigatinib tablet market in 2017. The presence of a large number of manufacturers coupled with high R&D investment by companies is expected to drive the regional market over the forecast period. Furthermore, increasing healthcare expenditure and rising patient awareness levels are also expected to propel growth during the same period.
Asia Pacific is anticipated to witness significant growth over the next eight years owing to an increase in disease burden and demand for cost-effective drugs that exhibit fewer side effects compared with other available therapies for cancer treatment.
Growth Factors:
- Increasing incidence of non-small cell lung cancer (NSCLC)
- Rising demand for targeted therapies for NSCLC
- Brigatinib’s potential to become a first-line treatment for NSCLC patients
- Growing number of clinical trials evaluating brigatinib’s efficacy and safety profile
- Availability of reimbursement for brigatinib in key markets
Scope Of The Report
Report Attributes
Report Details
Report Title
Brigatinib Tablet Market Research Report
By Type
30mg, 50mg, 180mg
By Application
Hospital, Pharmacy
By Companies
ARIAD Pharmaceuticals, ARIAD Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Brigatinib Tablet Market Report Segments:
The global Brigatinib Tablet market is segmented on the basis of:
Types
30mg, 50mg, 180mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ARIAD Pharmaceuticals
- ARIAD Pharmaceuticals
Highlights of The Brigatinib Tablet Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 30mg
- 50mg
- 180mg
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Brigatinib Tablet Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Brigatinib tablet is a cancer medication that is used to treat advanced or metastatic non-small cell lung cancer (NSCLC). Brigatinib tablet works by blocking the growth of tumor cells.
Some of the major players in the brigatinib tablet market are ARIAD Pharmaceuticals, ARIAD Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Brigatinib Tablet Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Brigatinib Tablet Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Brigatinib Tablet Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Brigatinib Tablet Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Brigatinib Tablet Market Size & Forecast, 2018-2028
4.5.1 Brigatinib Tablet Market Size and Y-o-Y Growth
4.5.2 Brigatinib Tablet Market Absolute $ Opportunity
Chapter 5 Global Brigatinib Tablet Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Brigatinib Tablet Market Size Forecast by Type
5.2.1 30mg
5.2.2 50mg
5.2.3 180mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Brigatinib Tablet Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Brigatinib Tablet Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Brigatinib Tablet Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Brigatinib Tablet Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Brigatinib Tablet Analysis and Forecast
9.1 Introduction
9.2 North America Brigatinib Tablet Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Brigatinib Tablet Market Size Forecast by Type
9.6.1 30mg
9.6.2 50mg
9.6.3 180mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Brigatinib Tablet Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Brigatinib Tablet Analysis and Forecast
10.1 Introduction
10.2 Europe Brigatinib Tablet Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Brigatinib Tablet Market Size Forecast by Type
10.6.1 30mg
10.6.2 50mg
10.6.3 180mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Brigatinib Tablet Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Brigatinib Tablet Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Brigatinib Tablet Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Brigatinib Tablet Market Size Forecast by Type
11.6.1 30mg
11.6.2 50mg
11.6.3 180mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Brigatinib Tablet Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Brigatinib Tablet Analysis and Forecast
12.1 Introduction
12.2 Latin America Brigatinib Tablet Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Brigatinib Tablet Market Size Forecast by Type
12.6.1 30mg
12.6.2 50mg
12.6.3 180mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Brigatinib Tablet Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Brigatinib Tablet Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Brigatinib Tablet Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Brigatinib Tablet Market Size Forecast by Type
13.6.1 30mg
13.6.2 50mg
13.6.3 180mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Brigatinib Tablet Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Brigatinib Tablet Market: Competitive Dashboard
14.2 Global Brigatinib Tablet Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ARIAD Pharmaceuticals
14.3.2 ARIAD Pharmaceuticals
